Clinical significance of combined detection of LPA and ACA in patients with pregnancy-induced hypertension

Objective To investigate the value of the combined detection of lysophosphatidic acid (LPA) and anti-cardiolipin antibody (ACA) for forecasting the development of pregnancy hypertension disease and pregnancy outcome.Methods Euzymelinked immunosorbent assay and biochemical treatment were respectively used to determinate the LPA level in plasma and anticardiolipin antibody positive rate of 142 cases of pregnancy-induced hypertension,including 53 cases of pregnancy-induced hypertension,mild preeclampsia 46 cases,and severe preeclampsia 43 cases,and normal late pregnant women (control group,58 cases),so to analyse the differences and correlation in patients with different degree pregnancy-induced hypertension and at the same time to evaluate its relationship with pregnancy outcome.Results The plasma LPA levels in patients with pregnancyinduced hypertension syndrome increased successively with the progression of the disease and were higher than that in the control group (P ＜ 0.05) ; the anticardiolipin antibody positive rate of severe PIH group was higher than that of other groups (P ＜ 0.05).The plasma level of LPA of the patients whose anticardiolipin antibody was positive in severe PIH group increased significantly,and the gestational age was small when onset,weight of perinatal low,and neonatal Apgar score low,which statistically differed from those of the negative group (P ＜ 0.05 or 0.01).Conclusions The severity of pregnancy-induced hypertension correlates with plasma LPA level; the more severe the disease becomes,the level of LPA is higher.Anticardiolipin antibody correlates with the pathogenesis of severe PIH.The combined detection of LPA and ACA can predict the severity of pregnancyinduced hypertension syndrome and pregnancy outcome,and it is expected to become the important measure of disease monitoring and prognosis. Key words: Pregnancy-induced hypertension (PIH) ;  Lysophosphatidic acid (LPA) ;  Anticardiolipin antibody (ACA)